BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Berenguer M, Pons J. Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle: Editorial. Liver Transpl 2012;18:755-60. [DOI: 10.1002/lt.23432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Zhang J, Yu Z, Li H, Yi S, Liu W, Yang Y, Wang G. Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report. Liver Research 2021;5:33-5. [DOI: 10.1016/j.livres.2020.10.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19(43): 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
4 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7(4): 649-661 [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
5 Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol 2019;2019:6298502. [PMID: 31636667 DOI: 10.1155/2019/6298502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Paik KY. Appropriate surgical therapy for patients with hepatocellular carcinoma beyond Milan criteria. Hepatobiliary Surg Nutr 2017;6:327-8. [PMID: 29152479 DOI: 10.21037/hbsn.2017.05.06] [Reference Citation Analysis]
7 Kumari R, Sahu MK, Tripathy A, Uthansingh K, Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat Oncol 2018;5:HEP08. [PMID: 31293776 DOI: 10.2217/hep-2018-0002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
8 Rodríguez-Perálvarez M, Gómez-Bravo MÁ, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J; Spanish Society of Liver Transplantation (SETH) Consensus Panel. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation 2021;105:602-7. [PMID: 32345868 DOI: 10.1097/TP.0000000000003281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
9 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
10 Nasser F, Cavalcante RN, Galastri FL, de Rezende MB, Felga GG, Travassos FB, De Fina B, Affonso BB. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. J Vasc Interv Radiol. 2014;25:1012-1017. [PMID: 24704346 DOI: 10.1016/j.jvir.2014.02.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
11 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
12 Dastjerdi MN, Kavoosi F, Valiani A, Esfandiari E, Sanaei M, Sobhanian S, Hakemi MG, Mobarakian M. Inhibitory Effect of Genistein on PLC/PRF5 Hepatocellular Carcinoma Cell Line. Int J Prev Med 2015;6:54. [PMID: 26180625 DOI: 10.4103/2008-7802.158914] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
13 Firl DJ, Sasaki K, Agopian VG, Gorgen A, Kimura S, Dumronggittigule W, Mcvey JC, Iesari S, Mennini G, Vitale A, Finkenstedt A, Onali S, Hoppe‐lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Agnes S, Vivarelli M, Tisone G, Ettorre GM, Otto G, Tsochatzis E, Rossi M, Viveiros A, Cillo U, Markmann JF, Ikegami T, Kaido T, Lai Q, Sapisochin G, Lerut J, Aucejo FN; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology 2019;71:569-82. [DOI: 10.1002/hep.30838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
14 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8:e53960. [PMID: 23349774 DOI: 10.1371/journal.pone.0053960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
16 Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, Xu X. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020;33:697-712. [PMID: 31985857 DOI: 10.1111/tri.13585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
17 Yilmaz C, Karaca CA, Iakobadze Z, Farajov R, Kilic K, Doganay L, Kilic M. Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma. Transplant Proc. 2018;50:3571-3576. [PMID: 30577240 DOI: 10.1016/j.transproceed.2018.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Qi X, Zhang X, Li Z, Hui J, Xiang Y, Chen J, Zhao J, Li J, Qi FZ, Xu Y. HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. Oncotarget 2016;7:62789-96. [PMID: 27566593 DOI: 10.18632/oncotarget.11558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Donat M, Alonso S, Pereira F, Ferrero E, Carrión L, Acin-Gándara D, Moreno E. Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation. Transplant Proc 2016;48:1968-77. [PMID: 27569930 DOI: 10.1016/j.transproceed.2016.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 Yoon YI, Song GW, Lee SG, Hwang S, Kim KH, Kim SH, Kang WH, Cho HD, Jwa EK, Kwon JH. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma. J Hepatol. 2018;68:1153-1162. [PMID: 29452208 DOI: 10.1016/j.jhep.2018.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
21 Lei J, Yan L. Outcome Comparisons Among the Hangzhou, Chengdu, and UCSF Criteria for Hepatocellular Carcinoma Liver Transplantation after Successful Downstaging Therapies. J Gastrointest Surg 2013;17:1116-22. [DOI: 10.1007/s11605-013-2140-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
22 Yang K, Lee T, Choi B, Park Y, Ryu J, Joo D, Chu C. Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings 2016;48:3317-22. [DOI: 10.1016/j.transproceed.2016.08.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Peloso A, Oldani G. Enlarged selection criteria for hepatocellular cancer: is the upper limit needed? Transl Gastroenterol Hepatol 2017;2:73. [PMID: 29034346 DOI: 10.21037/tgh.2017.09.02] [Reference Citation Analysis]
24 Fransen van de Putte DE, Makris M, Fischer K, Yee TT, Kirk L, van Erpecum KJ, Patch D, Posthouwer D, Mauser-bunschoten EP. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. Journal of Hepatology 2014;60:39-45. [DOI: 10.1016/j.jhep.2013.08.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
25 Nomura A, Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Onishi Y, Ogura Y, Fujishiro M. Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. Medicine (Baltimore) 2020;99:e21161. [PMID: 32664152 DOI: 10.1097/MD.0000000000021161] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
27 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Roayaie K, Roayaie S. Liver transplant for hepatocellular cancer: very small tumors, very large tumors, and waiting time. Clin Liver Dis. 2014;18:603-612. [PMID: 25017078 DOI: 10.1016/j.cld.2014.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
29 Tang A, Fowler KJ, Chernyak V, Chapman WC, Sirlin CB. LI-RADS and transplantation for hepatocellular carcinoma. Abdom Radiol 2018;43:193-202. [DOI: 10.1007/s00261-017-1210-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
30 Umgelter A, Hapfelmeier A, Kopp W, van Rosmalen M, Rogiers X, Guba M;  Eurotransplant Liver Advisory Committee. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions. Liver Transpl. 2017;23:1256-1265. [PMID: 28650098 DOI: 10.1002/lt.24805] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
31 Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: A single center analysis. World J Gastroenterol 2013; 19(36): 6077-6083 [PMID: 24106409 DOI: 10.3748/wjg.v19.i36.6077] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
32 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68 [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
33 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Teng F, Wang GH, Tao YF, Guo WY, Wang ZX, Ding GS, Shi XM, Fu ZR. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 2014; 20(31): 10900-10907 [PMID: 25152592 DOI: 10.3748/wjg.v20.i31.10900] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
35 Suh KS, Lee HW. Liver transplantation for advanced hepatocellular carcinoma: how far can we go? Hepat Oncol 2015;2:19-28. [PMID: 30190984 DOI: 10.2217/hep.14.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
36 Li B, Su H, Cao J, Zhang L. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma. Cytokine 2017;89:91-7. [PMID: 27663978 DOI: 10.1016/j.cyto.2016.08.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
37 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
38 Li R, Yan F, Liu L, Li H, Ren B, Hui Z, Ren X. Cytokine-induced killer cell therapy for the treatment of primary hepatocellular carcinoma subsequent to liver transplantation: A case report. Oncol Lett 2016;11:1885-8. [PMID: 26998094 DOI: 10.3892/ol.2016.4109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Bhatti ABH, Dar FS, Qureshi AI, Khan NY, Zia HH, Haider S, Shah NH, Rana A. Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience from Pakistan. J Clin Exp Hepatol 2019;9:704-9. [PMID: 31889751 DOI: 10.1016/j.jceh.2019.04.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
40 Rodríguez S, Balbinotto Neto G, Kiss G, Brandão A; Liver Transplantation Group. Cost-effectiveness of whole-body bone scans in the pre-liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil. Clin Transplant 2016;30:399-406. [PMID: 26783162 DOI: 10.1111/ctr.12699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, Teperman LW, Park JS, Kim YJ, Suh KS, Yoon JH. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg. 2016;263:842-850. [PMID: 26779979 DOI: 10.1097/sla.0000000000001578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 9.8] [Reference Citation Analysis]
42 Tang C, Yang JT, Chen HX, Liang XC, Liu HM, Chen P. A novel technique for central hepatectomy: Maintain the blood supply and biliary drainage on one side and the blood supply from the portal vein on the other. Exp Ther Med 2014;7:51-4. [PMID: 24348763 DOI: 10.3892/etm.2013.1367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol. 2013;25:180-186. [PMID: 23044808 DOI: 10.1097/meg.0b013e328359e550] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.9] [Reference Citation Analysis]
44 Finkenstedt A, Vikoler A, Portenkirchner M, Mülleder K, Maglione M, Margreiter C, Moser P, Vogel W, Bale R, Freund M, Luger A, Tilg H, Petersen J, Schneeberger S, Graziadei I, Zoller H, Glodny B. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016;36:688-95. [PMID: 26386273 DOI: 10.1111/liv.12966] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
45 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Lei JY, Wang WT, Yan LN. “Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma: A single-center analysis in mainland China. World J Gastroenterol 2013; 19(44): 8093-8098 [PMID: 24307805 DOI: 10.3748/wjg.v19.i44.8093] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
47 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019; 25(21): 2591-2602 [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
48 Wai CT, Woon WA, Tan YM, Lee KH, Tan KC. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation. Transplant Proc 2012;44:516-9. [PMID: 22410059 DOI: 10.1016/j.transproceed.2012.01.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]